The invention relates to a process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and its pharmaceutically acceptable salts, characterized in that 5-methoxy-l-indanone is used as a starting compound, followed by formation of the corresponding cyanohydrine, treatment with stannous chloride to give 2,3-dihydro-5-methoxy-1H-indene-i-carboxylic acid, followed by subsequent demethylation of the methoxy group, protection of the carboxylic acid group by esterification, formation of the corresponding ω-chloroalkyl ether, reaction with imidazole and final hydrolysis, thus obtaining 2,3-dihydro-5-[β-(1H-imidazol-1-yl)-alkoxy]-1H-indene-1-carboxylic acid. The process gives the intermediates in high purity and high yields so that the intermediates can be further processed without purification which results in an elevated overall yield.
本发明涉及一种制备 2,3-二氢-
1H-咪唑烷氧基
茚衍
生物及其药学上可接受的盐类的工艺,其特征在于使用 5-甲氧基-l-
茚酮作为起始化合物,然后形成相应的
氰基
水合物,用
氯化亚锡处理得到 2、3-二氢-
5-甲氧基-1H-茚-i-
羧酸,然后将甲氧基去甲基化,通过酯化作用保护
羧酸基团,形成相应的ω-
氯烷基醚,与
咪唑反应,最后
水解,从而得到 2,3-二氢-5-[β-(
1H-咪唑-1-基)-烷氧基]-1H-
茚-1-
羧酸。该工艺可获得高纯度和高产率的中间体,因此中间体无需纯化即可进一步加工,从而提高了总产率。